Vivani Medical, Inc. (“Vivani” or the “Company”), a ground-breaking biopharmaceutical entity known for its development of miniature, ultra long-acting, subdermal drug implants, has disclosed its intention to join the ranks of industry pioneers at the upcoming H.C. Wainwright 26th Annual Global Investment Conference, set to grace the city of New York on September 9-11, 2024.
The Innovative Journey Unfolds
During the conference, the luminary figure at Vivani’s helm, Chief Executive Officer Adam Mendelsohn, Ph.D., will carve out time to engage in one-on-one dialogues with discerning investors. This interaction is anticipated to be studded with insights, as Dr. Mendelsohn elaborates on the Company’s vision and strategy. The stage is set for a strategic discourse encompassing the Company’s trajectory, aspirations, and the ethos that propels its avant-garde offerings into the ever-evolving realm of biopharmaceuticals.
A Glimpse into the Future
For those keen on grasping Vivani’s essence and avant-garde solutions, an opportunity beckons in the form of a presentation slated for Wednesday, September 11, 2024, at the Adams Room (Fourth floor), Lotte New York Palace, New York, NY. The presentation, commencing at 10 a.m. Eastern Time, will be webcast for broader accessibility. Attendees can also access the presentation through the Vivani website under the “News & Events” tab on the Vivani Investor page.
Redefining Adherence in Pharmaceuticals
Vivani Medical boasts a distinctive edge in the biopharmaceutical landscape, leveraging the innovative NanoPortal™ platform to craft biopharmaceutical implants that usher in a new era of sustained drug delivery. The crown jewel of Vivani’s portfolio, NPM-115, introduces a miniature, six-month, subdermal GLP-1 (exenatide) implant tailored for steady weight management in obese or overweight individuals. Delving deeper into the pipeline, NPM-139 (semaglutide implant) emerges as a beacon of hope for chronic weight management seekers. With once-yearly administration as a unique selling point, NPM-139 extends a promise of improved patient experience. The impending NPM-119 trial is poised to intensify focus on a six-month, subdermal exenatide implant’s efficacy in treating type 2 diabetes. These visionary NanoPortal implants are a testament to Vivani’s commitment to circumventing challenges associated with daily or weekly medication regimes, thereby fostering greater patient adherence.
Looking Beyond the Horizon
In a landscape peppered with over 50 nascent GLP-1 entities in varying stages of clinical development, Vivani’s steadfast confidence in the efficacy of its miniature long-acting GLP-1 implants stands out. The Company’s unwavering belief in the transformative potential of its portfolio underscores its commitment to offering a compelling therapeutic avenue for patients, healthcare providers, and payers alike.
